Nymox Pharmaceutical Corporation (NYMX)
USD 0.2
(-0.05%)
USD 0.2
(-0.05%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 2.1 Million USD | 8.11% |
| 2021 | 1.94 Million USD | -11.33% |
| 2020 | 2.19 Million USD | 7.69% |
| 2019 | 2.04 Million USD | 90.04% |
| 2018 | 1.07 Million USD | -51.84% |
| 2017 | 2.23 Million USD | -17.37% |
| 2016 | 2.69 Million USD | -22.12% |
| 2015 | 3.46 Million USD | -38.16% |
| 2014 | 5.6 Million USD | -20.23% |
| 2013 | 7.02 Million USD | -23.63% |
| 2012 | 9.19 Million USD | -20.51% |
| 2011 | 11.57 Million USD | -29.25% |
| 2010 | 16.35 Million USD | 543.31% |
| 2009 | 2.54 Million USD | 102.29% |
| 2008 | 1.25 Million USD | -2.92% |
| 2007 | 1.29 Million USD | -39.62% |
| 2006 | 2.14 Million USD | -14.46% |
| 2005 | 2.5 Million USD | 22.07% |
| 2004 | 2.05 Million USD | 19.11% |
| 2003 | 1.72 Million USD | 17.15% |
| 2002 | 1.47 Million USD | 96.89% |
| 2001 | 747.49 Thousand USD | 130.87% |
| 2000 | 323.77 Thousand USD | -61.15% |
| 1999 | 833.34 Thousand USD | 176.12% |
| 1998 | 301.81 Thousand USD | 51.05% |
| 1997 | 199.8 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 3.14 Million USD | 32.6% |
| 2023 Q1 | 2.37 Million USD | 12.67% |
| 2022 Q2 | 2.24 Million USD | -14.69% |
| 2022 Q1 | 2.62 Million USD | 34.84% |
| 2022 FY | 2.1 Million USD | 8.11% |
| 2022 Q4 | 2.1 Million USD | -11.02% |
| 2022 Q3 | 2.36 Million USD | 5.62% |
| 2021 Q4 | 1.94 Million USD | -14.07% |
| 2021 Q3 | 2.26 Million USD | 15.54% |
| 2021 Q1 | 1.46 Million USD | -33.26% |
| 2021 Q2 | 1.96 Million USD | 33.81% |
| 2021 FY | 1.94 Million USD | -11.33% |
| 2020 Q2 | 2.11 Million USD | 9.79% |
| 2020 FY | 2.19 Million USD | 7.69% |
| 2020 Q4 | 2.19 Million USD | 15.93% |
| 2020 Q3 | 1.89 Million USD | -10.52% |
| 2020 Q1 | 1.93 Million USD | -5.44% |
| 2019 Q2 | 1.95 Million USD | 13.97% |
| 2019 Q1 | 1.71 Million USD | 59.31% |
| 2019 FY | 2.04 Million USD | 90.04% |
| 2019 Q4 | 2.04 Million USD | 12.64% |
| 2019 Q3 | 1.81 Million USD | -7.08% |
| 2018 Q4 | 1.07 Million USD | 26.5% |
| 2018 FY | 1.07 Million USD | -51.84% |
| 2018 Q2 | 1.61 Million USD | -19.17% |
| 2018 Q3 | 849 Thousand USD | -47.43% |
| 2018 Q1 | 1.99 Million USD | -10.4% |
| 2017 Q2 | 2.04 Million USD | -29.01% |
| 2017 Q1 | 2.87 Million USD | 6.58% |
| 2017 Q3 | 1.79 Million USD | -12.17% |
| 2017 FY | 2.23 Million USD | -17.37% |
| 2017 Q4 | 2.23 Million USD | 24.35% |
| 2016 Q1 | 2.53 Million USD | -26.84% |
| 2016 FY | 2.69 Million USD | -22.12% |
| 2016 Q2 | 2.6 Million USD | 2.7% |
| 2016 Q3 | 3.05 Million USD | 17.51% |
| 2016 Q4 | 2.69 Million USD | -11.8% |
| 2015 Q1 | 3.22 Million USD | -42.47% |
| 2015 Q3 | 3.78 Million USD | 17.88% |
| 2015 Q4 | 3.46 Million USD | -8.43% |
| 2015 FY | 3.46 Million USD | -38.16% |
| 2015 Q2 | 3.21 Million USD | -0.42% |
| 2014 Q4 | 5.6 Million USD | 1.19% |
| 2014 Q2 | 6.55 Million USD | -8.11% |
| 2014 Q1 | 7.13 Million USD | 1.5% |
| 2014 Q3 | 5.53 Million USD | -15.49% |
| 2014 FY | 5.6 Million USD | -20.23% |
| 2013 Q4 | 7.02 Million USD | 1.13% |
| 2013 Q2 | 8.21 Million USD | -6.57% |
| 2013 Q1 | 8.79 Million USD | -4.36% |
| 2013 FY | 7.02 Million USD | -23.63% |
| 2013 Q3 | 6.94 Million USD | -15.49% |
| 2012 FY | 9.19 Million USD | -20.51% |
| 2012 Q1 | 10.7 Million USD | -7.53% |
| 2012 Q4 | 9.19 Million USD | -6.83% |
| 2012 Q3 | 9.87 Million USD | -5.05% |
| 2012 Q2 | 10.39 Million USD | -2.83% |
| 2011 Q4 | 11.57 Million USD | -3.73% |
| 2011 Q2 | 12.68 Million USD | -4.8% |
| 2011 FY | 11.57 Million USD | -29.25% |
| 2011 Q1 | 13.32 Million USD | -18.54% |
| 2011 Q3 | 12.02 Million USD | -5.24% |
| 2010 Q1 | 2.13 Million USD | -16.17% |
| 2010 Q4 | 16.35 Million USD | 509.76% |
| 2010 FY | 16.35 Million USD | 543.31% |
| 2010 Q3 | 2.68 Million USD | 8.36% |
| 2010 Q2 | 2.47 Million USD | 16.15% |
| 2009 FY | 2.54 Million USD | 102.29% |
| 2009 Q2 | 2.18 Million USD | 4.71% |
| 2009 Q1 | 2.09 Million USD | 66.31% |
| 2009 Q3 | 2.19 Million USD | 0.35% |
| 2009 Q4 | 2.54 Million USD | 15.76% |
| 2008 Q3 | 1.49 Million USD | -2.42% |
| 2008 Q2 | 1.52 Million USD | 9.71% |
| 2008 FY | 1.25 Million USD | -2.92% |
| 2008 Q1 | 1.39 Million USD | 7.58% |
| 2008 Q4 | 1.25 Million USD | -15.71% |
| 2007 FY | 1.29 Million USD | -39.62% |
| 2007 Q4 | 1.29 Million USD | 19.43% |
| 2007 Q3 | 1.08 Million USD | 10.97% |
| 2007 Q2 | 976.96 Thousand USD | -40.83% |
| 2007 Q1 | 1.65 Million USD | -22.99% |
| 2006 Q2 | 1.77 Million USD | -32.81% |
| 2006 Q3 | 2.2 Million USD | 24.36% |
| 2006 Q4 | 2.14 Million USD | -2.76% |
| 2006 FY | 2.14 Million USD | -14.46% |
| 2006 Q1 | 2.63 Million USD | 5.27% |
| 2005 FY | 2.5 Million USD | 22.07% |
| 2005 Q1 | 2.11 Million USD | 3.17% |
| 2005 Q3 | 2.22 Million USD | 7.81% |
| 2005 Q2 | 2.06 Million USD | -2.57% |
| 2005 Q4 | 2.5 Million USD | 12.65% |
| 2004 FY | 2.05 Million USD | 19.11% |
| 2004 Q4 | 2.05 Million USD | 11.41% |
| 2004 Q3 | 1.84 Million USD | -12.74% |
| 2004 Q2 | 2.11 Million USD | 48.53% |
| 2004 Q1 | 1.42 Million USD | -17.51% |
| 2003 FY | 1.72 Million USD | 17.15% |
| 2003 Q3 | 1.37 Million USD | 50.88% |
| 2003 Q4 | 1.72 Million USD | 25.72% |
| 2003 Q1 | 824.4 Thousand USD | -43.98% |
| 2003 Q2 | 908.93 Thousand USD | 10.25% |
| 2002 Q3 | 905.53 Thousand USD | -13.57% |
| 2002 Q1 | 1.07 Million USD | 44.2% |
| 2002 FY | 1.47 Million USD | 96.89% |
| 2002 Q4 | 1.47 Million USD | 62.53% |
| 2002 Q2 | 1.04 Million USD | -2.81% |
| 2001 Q3 | 709.33 Thousand USD | -6.48% |
| 2001 Q4 | 747.49 Thousand USD | 5.38% |
| 2001 Q2 | 758.44 Thousand USD | 287.08% |
| 2001 Q1 | 195.94 Thousand USD | -39.48% |
| 2001 FY | 747.49 Thousand USD | 130.87% |
| 2000 Q1 | 604.06 Thousand USD | -27.51% |
| 2000 Q2 | 512.66 Thousand USD | -15.13% |
| 2000 Q3 | 276.44 Thousand USD | -46.08% |
| 2000 FY | 323.77 Thousand USD | -61.15% |
| 2000 Q4 | 323.77 Thousand USD | 17.12% |
| 1999 Q1 | 200.06 Thousand USD | -33.71% |
| 1999 Q3 | 199.83 Thousand USD | 100.86% |
| 1999 Q4 | 833.34 Thousand USD | 317.01% |
| 1999 FY | 833.34 Thousand USD | 176.12% |
| 1999 Q2 | 99.49 Thousand USD | -50.27% |
| 1998 Q4 | 301.81 Thousand USD | 43443126.46% |
| 1998 Q3 | -0.69 USD | -100.0% |
| 1998 Q1 | 99.92 Thousand USD | -49.99% |
| 1998 FY | 301.81 Thousand USD | 51.05% |
| 1998 Q2 | 100.05 Thousand USD | 0.13% |
| 1997 Q4 | 199.8 Thousand USD | 99.86% |
| 1997 FY | 199.8 Thousand USD | 0.0% |
| 1997 Q2 | 199.95 Thousand USD | 0.0% |
| 1997 Q3 | 99.97 Thousand USD | -50.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 99.372% |
| Alkermes plc | 933.53 Million USD | 99.774% |
| Agenus Inc. | 462.29 Million USD | 99.544% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.948% |
| Aptorum Group Limited | 5.25 Million USD | 59.918% |
| Ardelyx, Inc. | 130.76 Million USD | 98.389% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 99.56% |
| Bicycle Therapeutics plc | 224.41 Million USD | 99.061% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 98.382% |
| ChromaDex Corporation | 26.5 Million USD | 92.051% |
| Chimerix, Inc. | 19.74 Million USD | 89.329% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | 94.01% |
| Caribou Biosciences, Inc. | 72.56 Million USD | 97.096% |
| CRISPR Therapeutics AG | 346.76 Million USD | 99.392% |
| Precision BioSciences, Inc. | 140.92 Million USD | 98.505% |
| Dyadic International, Inc. | 2.34 Million USD | 9.982% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | 87.044% |
| Fortress Biotech, Inc. | 165.93 Million USD | 98.73% |
| Lantern Pharma Inc. | 2.73 Million USD | 23.093% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | 97.052% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | 40.29% |
| Incyte Corporation | 1.59 Billion USD | 99.868% |
| IO Biotech, Inc. | 17.55 Million USD | 87.998% |
| Jaguar Health, Inc. | 45.86 Million USD | 95.406% |
| Novavax, Inc. | 2.57 Billion USD | 99.918% |
| Janux Therapeutics, Inc. | 36.05 Million USD | 94.157% |
| Opthea Limited | 264.6 Million USD | 99.204% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 98.388% |
| ContextLogic Inc. | 206 Million USD | 98.977% |
| MiMedx Group, Inc. | 96.33 Million USD | 97.813% |
| Pyxis Oncology, Inc. | 48.02 Million USD | 95.612% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | 40.293% |
| NextCure, Inc. | 14.99 Million USD | 85.951% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | 47.872% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | 68.444% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | 95.492% |
| Vaxcyte, Inc. | 167.44 Million USD | 98.742% |
| PDS Biotechnology Corporation | 33.25 Million USD | 93.665% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 99.104% |
| Pharming Group N.V. | 244.07 Million USD | 99.137% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | 82.327% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 98.351% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | 68.111% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | 68.111% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 97.444% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | 68.282% |
| Acelyrin, Inc. | 86.35 Million USD | 97.56% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -62.172% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | 85.347% |
| Summit Therapeutics Inc. | 125.25 Million USD | 98.318% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | 77.772% |
| Senti Biosciences, Inc. | 52.57 Million USD | 95.992% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | 96.936% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 98.609% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -7.72% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -57.761% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 99.071% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | 77.506% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 99.074% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 99.574% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 80.695% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | 92.341% |
| Psyence Biomedical Ltd. | 12.1 Million USD | 82.594% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 99.567% |
| Immix Biopharma, Inc. | 3.72 Million USD | 43.387% |
| Keros Therapeutics, Inc. | 37.81 Million USD | 94.428% |
| MEI Pharma, Inc. | 8.35 Million USD | 74.782% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 92.738% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 99.394% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 98.556% |
| Fortress Biotech, Inc. | 165.93 Million USD | 98.73% |
| Precigen, Inc. | 41.64 Million USD | 94.94% |
| Clearside Biomedical, Inc. | 49.93 Million USD | 95.78% |
| AlloVir, Inc. | 45.01 Million USD | 95.319% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 98.383% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 98.471% |
| ImmuCell Corporation | 18.81 Million USD | 88.802% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | 92.535% |
| Onconetix, Inc. | 23.18 Million USD | 90.911% |
| PureTech Health plc | 125.58 Million USD | 98.322% |
| VYNE Therapeutics Inc. | 8.95 Million USD | 76.458% |
| Elevation Oncology, Inc. | 34.28 Million USD | 93.854% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | 13.824% |
| Seer, Inc. | 39.36 Million USD | 94.648% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | 96.592% |
| Innoviva, Inc. | 568.55 Million USD | 99.629% |
| Aadi Bioscience, Inc. | 27.22 Million USD | 92.262% |
| ESSA Pharma Inc. | 3.49 Million USD | 39.715% |
| GlycoMimetics, Inc. | 6.9 Million USD | 69.473% |
| GT Biopharma, Inc. | 6.63 Million USD | 68.235% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 99.203% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 99.226% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | 97.492% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | 78.443% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | 92.245% |
| Alzamend Neuro, Inc. | 3.22 Million USD | 34.682% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | 97.144% |
| Aptose Biosciences Inc. | 15.8 Million USD | 86.672% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | 80.914% |
| Soligenix, Inc. | 7.27 Million USD | 71.037% |
| Century Therapeutics, Inc. | 175.94 Million USD | 98.802% |
| Kura Oncology, Inc. | 51.66 Million USD | 95.922% |
| TScan Therapeutics, Inc. | 121.28 Million USD | 98.263% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | 49.02% |
| Ocean Biomedical, Inc. | 6.61 Million USD | 68.143% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 99.166% |
| Autolus Therapeutics plc | 263.9 Million USD | 99.202% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | 79.899% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | 97.629% |
| Eterna Therapeutics Inc. | 46.89 Million USD | 95.507% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 99.403% |
| GRI Bio, Inc. | 2.69 Million USD | 21.876% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -160.257% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | 93.223% |
| IGM Biosciences, Inc. | 220.17 Million USD | 99.043% |
| INmune Bio, Inc. | 18.86 Million USD | 88.829% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 99.178% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | 92.091% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | 22.491% |
| Entero Therapeutics, Inc. | 3.28 Million USD | 35.767% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | 96.396% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | 97.809% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 99.204% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 99.744% |
| Verastem, Inc. | 71.18 Million USD | 97.04% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 95.715% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | 94.538% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | 95.694% |
| Histogen Inc. | 5.69 Million USD | 63.016% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | 51.956% |
| Surrozen, Inc. | 8.14 Million USD | 74.131% |
| Organovo Holdings, Inc. | 2.74 Million USD | 23.326% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -571.323% |
| Ovid Therapeutics Inc. | 56.22 Million USD | 96.253% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 87.24% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | 95.877% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -154.815% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | 98.337% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | 80.515% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 98.604% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | 19.19% |
| Apollomics, Inc. | 14.15 Million USD | 85.113% |
| Amarin Corporation plc | 279.58 Million USD | 99.246% |
| Mesoblast Limited | 188.79 Million USD | 98.884% |
| Turnstone Biologics Corp. | 14.14 Million USD | 85.107% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 98.835% |
| Synaptogenix, Inc. | 5.52 Million USD | 61.895% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | 68.306% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 98.761% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | 75.377% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -19.894% |
| Exelixis, Inc. | 678.44 Million USD | 99.689% |
| Better Therapeutics, Inc. | 23.84 Million USD | 91.163% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 98.716% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 99.645% |
| NLS Pharmaceutics AG | 10.68 Million USD | 80.272% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -29.772% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 94.587% |
| Gritstone bio, Inc. | 125.91 Million USD | 98.327% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | 85.643% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | 58.594% |
| Avid Bioservices, Inc. | 275.66 Million USD | 99.236% |
| Insmed Incorporated | 1.66 Billion USD | 99.873% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | 72.615% |
| MediWound Ltd. | 27.18 Million USD | 92.25% |
| OmniAb, Inc. | 87.4 Million USD | 97.589% |
| Alector, Inc. | 487.66 Million USD | 99.568% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 99.478% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | 88.564% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 94.509% |
| Zai Lab Limited | 240.17 Million USD | 99.123% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 99.666% |
| Aura Biosciences, Inc. | 29.22 Million USD | 92.791% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | 97.784% |
| Immunic, Inc. | 25.36 Million USD | 91.694% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | 96.957% |
| Veracyte, Inc. | 93.71 Million USD | 97.752% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | 19.478% |
| FibroGen, Inc. | 585.72 Million USD | 99.64% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | 87.879% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -222.627% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | 62.744% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 99.972% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | 74.299% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | 97.492% |
| TG Therapeutics, Inc. | 169.08 Million USD | 98.754% |
| Galecto, Inc. | 5.89 Million USD | 64.264% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 74.565% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 99.92% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | 92.69% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | 83.306% |
| XBiotech Inc. | 8.39 Million USD | 74.908% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | 85.643% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | 96.038% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 99.42% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | 92.163% |
| Theravance Biopharma, Inc. | 169 Million USD | 98.753% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 99.827% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 99.579% |
| Vaxxinity, Inc. | 30.94 Million USD | 93.191% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 99.783% |
| Gain Therapeutics, Inc. | 6.03 Million USD | 65.064% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 99.717% |
| NexImmune, Inc. | 5.08 Million USD | 58.558% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -467.322% |
| Marker Therapeutics, Inc. | 3.07 Million USD | 31.476% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.97% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | 59.119% |
| Scopus BioPharma Inc. | 7.45 Million USD | 71.735% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | 91.987% |
| Ainos, Inc. | 7.39 Million USD | 71.505% |
| Pluri Inc. | 34.11 Million USD | 93.823% |
| Prothena Corporation plc | 135.01 Million USD | 98.439% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 99.133% |
| Celularity Inc. | 102.92 Million USD | 97.953% |
| Rallybio Corporation | 9.43 Million USD | 77.671% |
| Cue Biopharma, Inc. | 24.44 Million USD | 91.381% |
| MeiraGTx Holdings plc | 319.99 Million USD | 99.342% |
| Omeros Corporation | 403.25 Million USD | 99.477% |
| Humacyte, Inc. | 114.67 Million USD | 98.163% |
| Immunocore Holdings plc | 228.15 Million USD | 99.077% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | 56.779% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | 97.254% |
| Blueprint Medicines Corporation | 918.64 Million USD | 99.771% |
| CalciMedica, Inc. | 4.02 Million USD | 47.691% |
| Cabaletta Bio, Inc. | 17.45 Million USD | 87.927% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 98.633% |
| Scholar Rock Holding Corporation | 85.81 Million USD | 97.545% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 99.242% |
| Pulmatrix, Inc. | 15.96 Million USD | 86.801% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | 86.642% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | 91.437% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 99.16% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | 95.851% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 99.826% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 93.371% |
| Nutriband Inc. | 1.07 Million USD | -95.288% |
| Protara Therapeutics, Inc. | 10.63 Million USD | 80.184% |
| Vor Biopharma Inc. | 59.1 Million USD | 96.435% |
| Roivant Sciences Ltd. | 773.95 Million USD | 99.728% |
| Evogene Ltd. | 17.99 Million USD | 88.288% |
| ProKidney Corp. | 29.21 Million USD | 92.788% |
| Applied Therapeutics, Inc. | 71.97 Million USD | 97.073% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -198.872% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 99.888% |
| CorMedix Inc. | 11.91 Million USD | 82.32% |
| BioLineRx Ltd. | 50.7 Million USD | 95.844% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 98.59% |
| Galectin Therapeutics Inc. | 88.44 Million USD | 97.618% |
| Atai Life Sciences N.V. | 49.16 Million USD | 95.714% |
| Renovaro Biosciences Inc. | 31.15 Million USD | 93.236% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | 88.27% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | 98.309% |
| Sagimet Biosciences Inc. | 5.65 Million USD | 62.734% |
| MediciNova, Inc. | 3.89 Million USD | 45.857% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | 88.473% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -40.071% |
| GeoVax Labs, Inc. | 3.51 Million USD | 40.14% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 99.47% |
| Biomea Fusion, Inc. | 30.69 Million USD | 93.135% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 99.923% |
| Mereo BioPharma Group plc | 15.96 Million USD | 86.8% |
| Cullinan Oncology, Inc. | 31.2 Million USD | 93.247% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | 96.41% |
| Absci Corporation | 58.3 Million USD | 96.386% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | 88.938% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | 93.428% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | 97.145% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | 97.592% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | 93.761% |
| Allakos Inc. | 74.79 Million USD | 97.183% |
| Imunon, Inc. | 8.53 Million USD | 75.3% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | 90.636% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 98.165% |
| BioAtla, Inc. | 48.98 Million USD | 95.699% |
| NLS Pharmaceutics AG | 10.68 Million USD | 80.272% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | 24.181% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 98.387% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | 85.178% |
| XOMA Corporation | 145.58 Million USD | 98.553% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | 93.741% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 96.936% |
| aTyr Pharma, Inc. | 31.59 Million USD | 93.332% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | 96.592% |
| Akero Therapeutics, Inc. | 44.96 Million USD | 95.314% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | 95.647% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | 26.585% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | 74.173% |
| Akari Therapeutics, Plc | 4.58 Million USD | 54.036% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | 88.118% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 99.872% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -421.653% |
| UroGen Pharma Ltd. | 243.52 Million USD | 99.135% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 99.344% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | 23.702% |
| Orgenesis Inc. | 35.53 Million USD | 94.071% |
| Entera Bio Ltd. | 1.37 Million USD | -52.792% |
| GH Research PLC | 6.7 Million USD | 68.557% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | 69.015% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | 88.808% |
| Xencor, Inc. | 283.55 Million USD | 99.257% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | 29.43% |
| Replimune Group, Inc. | 113.21 Million USD | 98.139% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | 43.92% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | 97.965% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -421.653% |
| Portage Biotech Inc. | 4.45 Million USD | 52.652% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -40.071% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | 90.859% |
| OncoCyte Corporation | 49.29 Million USD | 95.726% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | 49.067% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -164.206% |
| Purple Biotech Ltd. | 10 Million USD | 78.941% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | 63.585% |
| scPharmaceuticals Inc. | 57.26 Million USD | 96.32% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | 82.992% |
| HilleVax, Inc. | 78.9 Million USD | 97.33% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | 58.277% |
| Tharimmune, Inc. | 1.81 Million USD | -16.085% |
| Genprex, Inc. | 3.25 Million USD | 35.253% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | 92.231% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | 59.759% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -922.816% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -487.648% |
| OKYO Pharma Limited | 7.42 Million USD | 71.607% |
| Savara Inc. | 37.19 Million USD | 94.335% |
| Curis, Inc. | 57.61 Million USD | 96.343% |
| Daré Bioscience, Inc. | 26.32 Million USD | 91.998% |
| Carmell Therapeutics Corporation | 39.19 Million USD | 94.625% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -45.914% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | 89.879% |
| BeiGene, Ltd. | 2.23 Billion USD | 99.906% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 90.103% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 99.197% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | 90.096% |
| Erasca, Inc. | 78.61 Million USD | 97.32% |
| bluebird bio, Inc. | 424.62 Million USD | 99.504% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -221.556% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 99.889% |
| DBV Technologies S.A. | 42.8 Million USD | 95.077% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -221.556% |
| Moderna, Inc. | 4.57 Billion USD | 99.954% |
| Vincerx Pharma, Inc. | 6.99 Million USD | 69.878% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -27.234% |
| Molecular Templates, Inc. | 31.17 Million USD | 93.241% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | 87.657% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 99.642% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | 98.308% |
| Spruce Biosciences, Inc. | 27.43 Million USD | 92.321% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | 94.22% |
| Cogent Biosciences, Inc. | 55.63 Million USD | 96.213% |
| MacroGenics, Inc. | 154.2 Million USD | 98.634% |
| RenovoRx, Inc. | 4.46 Million USD | 52.821% |
| Adicet Bio, Inc. | 37.12 Million USD | 94.324% |
| Prime Medicine, Inc. | 60.78 Million USD | 96.533% |
| Aditxt, Inc. | 28.53 Million USD | 92.615% |
| Adagene Inc. | 45.16 Million USD | 95.335% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -1066.015% |
| Quantum-Si incorporated | 26.63 Million USD | 92.088% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 99.698% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | 30.746% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | 98.167% |
| SciSparc Ltd. | 1.59 Million USD | -32.1% |
| Vericel Corporation | 127.7 Million USD | 98.35% |
| Revelation Biosciences, Inc. | 5.56 Million USD | 62.138% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | 97.532% |
| Generation Bio Co. | 171.63 Million USD | 98.772% |
| Astria Therapeutics, Inc. | 11.55 Million USD | 81.758% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | 94.963% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 99.166% |
| Invivyd, Inc. | 51.71 Million USD | 95.926% |
| Relay Therapeutics, Inc. | 91.97 Million USD | 97.709% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | 67.611% |
| Spero Therapeutics, Inc. | 75.49 Million USD | 97.209% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -106.366% |
| 2seventy bio, Inc. | 310.12 Million USD | 99.321% |
| ADMA Biologics, Inc. | 193.97 Million USD | 98.914% |
| Clene Inc. | 38.95 Million USD | 94.591% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | 94.169% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 99.18% |
| GeoVax Labs, Inc. | 3.51 Million USD | 40.14% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 98.893% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | 82.701% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 98.938% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | 82.722% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 95.621% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | 96.013% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 99.43% |
| Evaxion Biotech A/S | 17.61 Million USD | 88.04% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 98.691% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 98.625% |
| Trevena, Inc. | 48.26 Million USD | 95.634% |
| Surrozen, Inc. | 8.14 Million USD | 74.131% |
| Tyra Biosciences, Inc. | 21.59 Million USD | 90.243% |
| Cingulate Inc. | 10.36 Million USD | 79.664% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | 23.382% |
| Unity Biotechnology, Inc. | 37.29 Million USD | 94.35% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | 41.252% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | 83.977% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 99.336% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | 91.521% |
| Clearmind Medicine Inc. | 3.61 Million USD | 41.634% |
| Kronos Bio, Inc. | 54.2 Million USD | 96.113% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | 95.521% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | 90.742% |
| Viking Therapeutics, Inc. | 20.07 Million USD | 89.502% |
| Statera Biopharma, Inc. | 22.67 Million USD | 90.708% |
| ImmunityBio, Inc. | 1.09 Billion USD | 99.807% |
| Korro Bio, Inc. | 51.75 Million USD | 95.929% |
| Kineta, Inc. | 7.22 Million USD | 70.825% |
| BioVie Inc. | 9.7 Million USD | 78.283% |
| Codexis, Inc. | 49.94 Million USD | 95.781% |
| Celularity Inc. | 102.92 Million USD | 97.953% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | 97.811% |
| Celcuity Inc. | 51.45 Million USD | 95.905% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -510.381% |
| Cibus, Inc. | 206.11 Million USD | 98.978% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | 95.039% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 92.0% |
| IN8bio, Inc. | 8.77 Million USD | 75.98% |
| Kodiak Sciences Inc. | 213.59 Million USD | 99.014% |
| Annexon, Inc. | 47.11 Million USD | 95.528% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | 97.647% |
| Assembly Biosciences, Inc. | 96.37 Million USD | 97.814% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | 84.608% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 99.919% |
| Eyenovia, Inc. | 19.78 Million USD | 89.348% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 98.81% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | 72.569% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | 91.257% |
| Arcellx, Inc. | 339.75 Million USD | 99.38% |
| Cardiff Oncology, Inc. | 11.89 Million USD | 82.291% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 99.142% |
| Regulus Therapeutics Inc. | 9.56 Million USD | 77.967% |
| Moolec Science SA | 13.94 Million USD | 84.891% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | 95.117% |
| Geron Corporation | 146.12 Million USD | 98.558% |
| LAVA Therapeutics N.V. | 50.53 Million USD | 95.83% |
| Royalty Pharma plc | 6.29 Billion USD | 99.967% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | 94.703% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -615.678% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | 14.359% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 98.886% |
| Humacyte, Inc. | 114.67 Million USD | 98.163% |
| Structure Therapeutics Inc. | 29.05 Million USD | 92.747% |
| 89bio, Inc. | 59.96 Million USD | 96.486% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | 92.038% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -76.171% |
| Genelux Corporation | 8.42 Million USD | 74.976% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | 69.268% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 98.454% |
| Notable Labs, Ltd. | 4.42 Million USD | 52.406% |
| Liquidia Corporation | 73.13 Million USD | 97.119% |
| Mustang Bio, Inc. | 17.61 Million USD | 88.041% |
| Immunovant, Inc. | 48.95 Million USD | 95.696% |
| Quantum-Si incorporated | 26.63 Million USD | 92.088% |
| Arbutus Biopharma Corporation | 38.38 Million USD | 94.511% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | 32.098% |
| Vera Therapeutics, Inc. | 73.86 Million USD | 97.147% |
| Acasti Pharma Inc. | 11.55 Million USD | 81.769% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | 90.68% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | 22.491% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | 94.286% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -54.603% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | 65.436% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | 91.516% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | 90.912% |
| PepGen Inc. | 34.63 Million USD | 93.916% |
| Moleculin Biotech, Inc. | 12.14 Million USD | 82.65% |
| United Therapeutics Corporation | 1.18 Billion USD | 99.822% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | 69.831% |
| Solid Biosciences Inc. | 38.45 Million USD | 94.521% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | 75.377% |
| Immuneering Corporation | 12 Million USD | 82.454% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -571.323% |
| Silo Pharma, Inc. | 1.56 Million USD | -34.266% |
| Belite Bio, Inc | 4.21 Million USD | 49.964% |
| XOMA Corporation | 145.58 Million USD | 98.553% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | 13.221% |
| Bionomics Limited | 10.15 Million USD | 79.259% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | 90.196% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | 90.804% |
| uniQure N.V. | 624.01 Million USD | 99.662% |
| Cassava Sciences, Inc. | 14.19 Million USD | 85.157% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -1066.015% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 98.762% |
| Forte Biosciences, Inc. | 3.66 Million USD | 42.526% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -708.572% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | 68.771% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | 72.569% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | 87.879% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | 80.062% |
| Altimmune, Inc. | 16.54 Million USD | 87.262% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 99.659% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | 90.804% |
| Compugen Ltd. | 55.77 Million USD | 96.222% |
| Peak Bio, Inc. | 20.75 Million USD | 89.847% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | 98.093% |
| Benitec Biopharma Inc. | 4.96 Million USD | 57.537% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 98.665% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | 97.197% |
| Zura Bio Limited | 21.29 Million USD | 90.104% |
| PolyPid Ltd. | 17.46 Million USD | 87.938% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | 98.125% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | 97.197% |
| Instil Bio, Inc. | 99.8 Million USD | 97.889% |
| argenx SE | 444.95 Million USD | 99.526% |
| Immunome, Inc. | 28.65 Million USD | 92.648% |
| Compass Therapeutics, Inc. | 8.33 Million USD | 74.727% |
| Verona Pharma plc | 58.84 Million USD | 96.419% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | 85.442% |
| Shattuck Labs, Inc. | 14.85 Million USD | 85.82% |
| CervoMed Inc. | 2.59 Million USD | 18.829% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | 56.771% |
| Plus Therapeutics, Inc. | 12.73 Million USD | 83.456% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | 80.0% |
| Moolec Science SA | 13.94 Million USD | 84.891% |
| Enveric Biosciences, Inc. | 2.34 Million USD | 10.092% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | 96.21% |
| AnaptysBio, Inc. | 364.28 Million USD | 99.422% |
| Design Therapeutics, Inc. | 11.95 Million USD | 82.377% |
| Leap Therapeutics, Inc. | 12.68 Million USD | 83.389% |
| NeurAxis, Inc. | 1.91 Million USD | -10.156% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | 94.587% |
| Lumos Pharma, Inc. | 13.33 Million USD | 84.197% |
| Achilles Therapeutics plc | 19.08 Million USD | 88.961% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | 85.442% |
| 180 Life Sciences Corp. | 5.38 Million USD | 60.889% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | 91.067% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | 90.742% |
| Nutriband Inc. | 1.07 Million USD | -95.288% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | 93.114% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | 85.48% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 99.475% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | 93.512% |
| MoonLake Immunotherapeutics | 13.04 Million USD | 83.853% |
| Palisade Bio, Inc. | 2.73 Million USD | 23.074% |
| Tourmaline Bio, Inc. | 5.25 Million USD | 59.89% |
| Beam Therapeutics Inc. | 478.38 Million USD | 99.56% |
| Neurogene Inc. | 36.54 Million USD | 94.235% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 99.471% |
| AEON Biopharma, Inc. | 159.88 Million USD | 98.682% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | 95.578% |
| Sesen Bio, Inc. | 30.98 Million USD | 93.2% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | 91.884% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | 72.284% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 98.924% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 98.903% |
| Athira Pharma, Inc. | 30.05 Million USD | 92.99% |
| Vaccinex, Inc. | 5.94 Million USD | 64.541% |
| HCW Biologics Inc. | 15.05 Million USD | 86.002% |
| XOMA Corporation | 145.58 Million USD | 98.553% |
| Nektar Therapeutics | 267.04 Million USD | 99.211% |
| Arvinas, Inc. | 644.6 Million USD | 99.673% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | 88.118% |
| Merus N.V. | 102.15 Million USD | 97.937% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 98.56% |
| Quince Therapeutics, Inc. | 95.12 Million USD | 97.785% |
| Rezolute, Inc. | 11.73 Million USD | 82.044% |
| Clene Inc. | 38.95 Million USD | 94.591% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | 26.002% |
| BeyondSpring Inc. | 48.26 Million USD | 95.635% |
| Synlogic, Inc. | 32.89 Million USD | 93.595% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | 85.581% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -28.947% |
| Peak Bio, Inc. | 20.75 Million USD | 89.847% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | 96.68% |
| Krystal Biotech, Inc. | 39.71 Million USD | 94.695% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 99.441% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | 97.884% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -386.913% |
| MannKind Corporation | 721.36 Million USD | 99.708% |
| Ikena Oncology, Inc. | 22.33 Million USD | 90.566% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -1.007% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | 97.946% |
| Gossamer Bio, Inc. | 249.14 Million USD | 99.154% |
| CohBar, Inc. | 1.03 Million USD | -103.843% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | 80.288% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | 88.938% |
| Legend Biotech Corporation | 589.93 Million USD | 99.643% |
| Mural Oncology plc | 37.92 Million USD | 94.445% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 98.411% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | 8.205% |
| Disc Medicine, Inc. | 22.87 Million USD | 90.789% |
| Champions Oncology, Inc. | 28.03 Million USD | 92.484% |
| REGENXBIO Inc. | 262.22 Million USD | 99.197% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | 37.28% |
| Anavex Life Sciences Corp. | 12.53 Million USD | 83.19% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | 84.313% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | 90.064% |
| Vaxart, Inc. | 34.02 Million USD | 93.807% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | 89.666% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | 92.615% |
| Cellectis S.A. | 249.57 Million USD | 99.156% |
| Longeveron Inc. | 5.33 Million USD | 60.521% |
| Repare Therapeutics Inc. | 41.81 Million USD | 94.962% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 99.912% |
| Inozyme Pharma, Inc. | 60.36 Million USD | 96.51% |
| Revolution Medicines, Inc. | 262.39 Million USD | 99.197% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | 75.574% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | 82.146% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | 84.996% |
| Anixa Biosciences, Inc. | 2.15 Million USD | 2.046% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.959% |
| Denali Therapeutics Inc. | 122.96 Million USD | 98.286% |
| Revelation Biosciences, Inc. | 5.56 Million USD | 62.138% |
| Veru Inc. | 32.81 Million USD | 93.579% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | 69.326% |
| Cingulate Inc. | 10.36 Million USD | 79.664% |
| Passage Bio, Inc. | 39.26 Million USD | 94.633% |
| Context Therapeutics Inc. | 4.19 Million USD | 49.734% |
| Exicure, Inc. | 8.54 Million USD | 75.354% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | 92.86% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | 79.907% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | 90.441% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 98.707% |
| Nuvalent, Inc. | 31.82 Million USD | 93.379% |
| ABVC BioPharma, Inc. | 6.36 Million USD | 66.88% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | 96.657% |
| Unicycive Therapeutics, Inc. | 18 Million USD | 88.294% |
| OmniAb, Inc. | 87.4 Million USD | 97.589% |
| Anew Medical, Inc. | 8.24 Million USD | 74.435% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | 94.497% |
| Lipocine Inc. | 2.63 Million USD | 19.936% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | 91.98% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | 94.76% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | 92.091% |
| G1 Therapeutics, Inc. | 86.15 Million USD | 97.554% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | 60.989% |
| Sage Therapeutics, Inc. | 82.74 Million USD | 97.454% |
| Ocugen, Inc. | 23.98 Million USD | 91.215% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | 95.46% |
| Q32 Bio Inc. | 233.12 Million USD | 99.096% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | 76.759% |
| Alumis Inc. Common Stock | 53.5 Million USD | 96.062% |
| Equillium, Inc. | 27.95 Million USD | 92.463% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 98.98% |
| Coya Therapeutics, Inc. | 5.62 Million USD | 62.553% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | 65.645% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 98.661% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 96.965% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 78.876% |
| Dominari Holdings Inc. | 4.63 Million USD | 54.542% |
| Edesa Biotech, Inc. | 1.84 Million USD | -14.409% |
| vTv Therapeutics Inc. | 29.56 Million USD | 92.874% |
| Bio-Techne Corporation | 744.34 Million USD | 99.717% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 98.329% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 99.388% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | 94.807% |
| Candel Therapeutics, Inc. | 28.95 Million USD | 92.724% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | 97.719% |
| Nkarta, Inc. | 105.6 Million USD | 98.005% |
| BioCardia, Inc. | 4.59 Million USD | 54.096% |
| Iterum Therapeutics plc | 32.66 Million USD | 93.549% |